Your Groups
-
None
-
amunozvazquez46769 updated their profile 3 months ago
Schedule for: February 18, 2026 at 9:25 am
-
barokiaraj changed their profile photo 3 months ago
Schedule for: February 18, 2026 at 9:17 am
-
amunozvazquez46769 changed their profile photo 3 months ago
Schedule for: February 18, 2026 at 9:15 am
-
462310 and
amunozvazquez46769 are now connected 3 months agoSchedule for: February 18, 2026 at 9:15 am
-
marena and
amunozvazquez46769 are now connected 3 months agoSchedule for: February 18, 2026 at 8:38 am
-
marena updated their profile 3 months ago
Schedule for: February 18, 2026 at 8:29 am
-
marena changed their profile photo 3 months ago
Schedule for: February 18, 2026 at 8:28 am
-
physicianmembertest posted an update 4 months ago
Schedule for: January 15, 2026 at 12:04 am
The subcutaneous injection of amivantamab and hyaluronidase-lpuj was evaluated in PALOMA-3, a randomized, open-label, multicenter, multiregional trial in adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR-exon 19 deletions or exon 21 L858R substitution mutations.…
fda.gov
FDA approves amivantamab and hyaluronidase-lpuj
On December 17, 2025, the Food and Drug Administration approved amivantamab and hyaluronidase-lpuj (Rybrevant Faspro, Janssen Biotech, Inc.) for subcutaneous injection for adult patients
-
physicianmembertest updated their profile 4 months ago
Schedule for: January 14, 2026 at 1:53 pm
-
superadmin posted an update 4 months ago
Schedule for: January 9, 2026 at 11:00 am
test
Test
- Load More
